Big Bank Analysts See Apple Stock Weakness as Buying Opportunity and Other Insights Now

Apple Inc. (NASDAQ:AAPL): JPMorgan said Apple’s IR department has stated that the iPhone 5 pre-orders that have not been shipped yet are not included in the 5 million figure. The analyst thinks that investors should focus on the quickness of the global roll out and orders and views weakness as a buying opportunity. The shares also had positive mention at Bank of America Merrill Lynch.

Don’t Miss: AT&T versus Verizon: Who is Winning the iPhone 5 Launch?

Monsanto Co. (NYSE:MON) price target was increased by Argus to $109 before company’s Q4 report, due to valuation and the hope ┬áthat Monsanto will see some benefits from the drought. The firm keeps a Buy rating on the stock.

Genomic Health Inc. (NASDAQ:GHDX): Piper Jaffray claims that it discovered changes in the CMS Medicare Administrative Contractor for California, and Noridian won the Jurisdiction E contract from current provider Palmetto. Piper does not believe that the change will affect near-time impact to Genomic Health’s Oncotype breast and colon assays, but thinks that it could indicate possible reimbursement uncertainty longer term. Piper maintains its Overweight rating on the stock.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>